Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Autosomal dominant hypercholesterolemia (ADH; OMIM144400), a risk factor for coronary heart disease, is characterized by an increase in low-density lipoprotein cholesterol levels that is associated with mutations in the genes LDLR (encoding low-density lipoprotein receptor) or APOB (encoding apolipoprotein B). We mapped a third locus associated with ADH, HCHOLA3 at 1p32, and now report two mutations in the gene PCSK9 (encoding proprotein convertase subtilisin/kexin type 9) that cause ADH. PCSK9 encodes NARC-1 (neural apoptosis regulated convertase), a newly identified human subtilase that is highly expressed in the liver and contributes to cholesterol homeostasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“mutations conveying gain or loss of function of PCSK9 result in a higher or lower level of LDL cholesterol, respectively, which in turn is associated with a corresponding higher 7 or lower 6 risk of incident coronary heart disease.”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [7]
In the citing paper
“In 2003, Abifadel and colleagues identified gain-of-function mutations in the PCSK9 gene causative of familial hypercholesterolemia, an autosomal dominant trait characterized by an elevation in circulating low-density lipoprotein cholesterol (LDL-C) and premature coronary heart disease (CHD) risk (2).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [2]
In the citing paper
“Autosomal Dominant Hypercholesterolemia (ADH), due to mutations in the LDLR, APOB or PCSK9 genes, is characterized by an isolated elevation of cholesterol due to high levels of low-density lipoproteins (LDL).”
From Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation (2013) · cites this paper as Abifadel M et al. 2003
In the citing paper
“ADH is genetically heterogeneous and associated with mutations in the well-known LDLR (low density lipoprotein receptor) (FH, OMIM #606945), APOB (apolipoprotein B-100) (FDB, OMIM # 144010) and PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9, Abifadel M et al. 2003) genes.”
From Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation (2013) · cites this paper as Abifadel M et al. 2003
In the citing paper
“Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the subtilisin family of proprotein convertases (PCs) [2], with an established role in the systemic control of blood cholesterol and a lesser-characterized role in neuronal development and apoptosis [3,4].”
From PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling (2012) · cites this paper as [3]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
RGD AND OTHER RECOGNITION SEQUENCES FOR INTEGRINS
Ruoslahti, E. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.697 · Cited by 3,191
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
Self-citationA proteolytic pathway that controls the cholesterol content of membranes, cells, and blood
Brown, M. S., & Goldstein, J. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11041 · Cited by 1,134
A Third Major Locus for Autosomal Dominant Hypercholesterolemia Maps to 1p34.1-p32
Varret, M., Rabès, J.-P., Saint-Jore, B., Cenarro, A., Marinoni, J.-C., Civeira, F., Devillers, M., Krempf, M., Coulon, M., Thiart, R., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302370 · Cited by 175
Self-citationBiosynthesis and Cellular Trafficking of the Convertase SKI-1/S1P
Elagoz, A., Benjannet, S., Mammarbassi, A., Wickham, L., & Seidah, N. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109011200 · Cited by 113
Self-citationHunt, S. C., Hopkins, P. N., Bulka, K., McDermott, M. T., Thorne, T. L., Wardell, B. B., Bowen, B. R., Ballinger, D. G., Skolnick, M. H., & Samuels, M. E. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.4.1089 · Cited by 109
Cited by
Items 801–900 of 1,044
Taghizadeh, E., Esfehani, R. J., Sahebkar, A., Parizadeh, S. M., Rostami, D., Mirinezhad, M., Poursheikhani, A., Ghayour‐Mobarhan, M., & Pasdar, A. (2019) · IUBMB Life · doi:10.1002/iub.2073 · Cited by 49
di Mauro, G., Zinzi, A., Scavone, C., Mascolo, A., Gaio, M., Sportiello, L., Ferrajolo, C., Rafaniello, C., Rossi, F., & Capuano, A. (2020) · Drug Safety · doi:10.1007/s40264-020-01021-3 · Cited by 49
Wang, J., Wang, Y., Yang, X., Lin, P. C., Liu, N., Li, X., Zhang, B., & Guo, S. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.02.191 · Cited by 49
Cohen, H., Stefanutti, C., Giacomo, S. D., Morozzi, C., Widhalm, K., Bjelakovic, B. B., Berni, A., Martino, F., & Bosco, G. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00926-3 · Cited by 49
Adipocyte function and the development of cardiometabolic disease
Giroud, M., Jodeleit, H., Prentice, K. J., & Bartelt, A. (2021) · The Journal of Physiology · doi:10.1113/jp281979 · Cited by 49
Human genetics as a foundation for innovative drug development
Kamb, A., Harper, S., & Stefánsson, K. (2013) · Nature Biotechnology · doi:10.1038/nbt.2732 · Cited by 49
Katayama, H., Paczesny, S., Prentice, R. L., Aragaki, A. K., Faça, V. M., Pitteri, S. J., Zhang, Q., Wang, H., Silva, M., Kennedy, J. J., et al. (2009) · Genome Medicine · doi:10.1186/gm47 · Cited by 49
Tichý, L., Freiberger, T., Zapletalová, P., Soška, V., Ravčuková, B., & Fajkusová, L. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.05.014 · Cited by 49
Bordicchia, M., Spannella, F., Ferretti, G., Bacchetti, T., Vignini, A., Pentima, C. D., Mazzanti, L., & Sarzani, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020245 · Cited by 49
Simple Genetics for a Complex Disease
Cohen, J. C., & Hobbs, H. H. (2013) · Science · doi:10.1126/science.1239101 · Cited by 48
Functional characterization and classification of frequent low-density lipoprotein receptor variants
Etxebarria, A., Benito-Vicente, A., Palacios, L., Stef, M., Cenarro, A., Civeira, F., Ostolaza, H., & Martin, C. (2015) · Human Mutation · doi:10.1002/humu.22721 · Cited by 48
PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?
Mannarino, M. R., Sahebkar, A., Bianconi, V., Serban, M.-C., Banach, M., & Pirro, M. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.05.012 · Cited by 48
Srivastava, R. A. K. (2023) · Cells · doi:10.3390/cells12121648 · Cited by 48
Drug Therapy of Hypercholesterolaemia in Children and Adolescents
Braamskamp, M. J. A. M., Wijburg, F. A., & Wiegman, A. (2012) · Drugs · doi:10.2165/11632810-000000000-00000 · Cited by 48
Kurano, M., Tsukamoto, K., Kamitsuji, S., Kamatani, N., Hara, M., Ishikawa, T., Kim, B.-J., Moon, S., Kim, Y. J., & Teramoto, T. (2016) · Journal of Human Genetics · doi:10.1038/jhg.2015.170 · Cited by 48
Athavale, D., Chouhan, S., Pandey, V., Mayengbam, S. S., Singh, S., & Bhat, M. K. (2018) · Cancer & Metabolism · doi:10.1186/s40170-018-0187-2 · Cited by 48
Current Status of Familial Hypercholesterolemia in China: A Need for Patient FH Registry Systems
Chen, P., Chen, X., & Zhang, S. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00280 · Cited by 48
Esteghamat, F., Broughton, J. S., Smith, E., CARDONE, R. L., Tyagi, T., Guerra, M. T., Szabó, A., Ugwu, N., Mani, M. V., Azari, B. M., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0470-3 · Cited by 48
Huijgen, R., Sjouke, B., Vis, K., de Randamie, J. S. E., Defesche, J. C., Kastelein, J. J. P., Hovingh, G. K., & Fouchier, S. W. (2012) · Human Mutation · doi:10.1002/humu.21660 · Cited by 46
Refaie, S., Gagnon, S., Gagnon, H., Desjardins, R., D’Anjou, F., D’Orléans-Juste, P., Zhu, X., Steiner, D. F., Seidah, N. G., Lazure, C., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.323220 · Cited by 48
Self-citationHow to identify gene–environment interactions in a multifactorial disease: CHD as an example
Talmud, P. J. (2004) · Proceedings of the Nutrition Society · doi:10.1079/pns2003311 · Cited by 46
The epigenetic drug 5-azacytidine interferes with cholesterol and lipid metabolism
Poirier, S., Samami, S., Mamarbachi, M., Demers, A., Chang, T. Y., Vance, D. E., Hatch, G. M., & Mayer, G. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.563650 · Cited by 47
Besseling, J., Sjouke, B., & Kastelein, J. J. P. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.011 · Cited by 47
Anti-PCSK9 therapies for the treatment of hypercholesterolemia
Hooper, A. J., & Burnett, J. R. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.748743 · Cited by 46
The Genetic Architecture of Coronary Artery Disease: Current Knowledge and Future Opportunities
Hartiala, J., Schwartzman, W. S., Gabbay, J., Ghazalpour, A., Bennett, B. J., & Allayee, H. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0641-6 · Cited by 47
Peyot, M.-L., Roubtsova, A., Lussier, R., Chamberland, A., Essalmani, R., Murthy Madiraju, S. R., Seidah, N. G., Prentki, M., & Prat, A. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.158968 · Cited by 35
Self-citationHsu, L., Teng, M., Ko, Y., Chang, C., Wu, S., Wang, C., & Hu, C.-F. (2009) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2009.032 · Cited by 47
Awan, Z. A., Baass, A. W., & Genest, J. J. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.225946 · Cited by 47
Stairs instead of elevators at the workplace decreases PCSK 9 levels in a healthy population
Kamani, C. H., Gencer, B., Montecucco, F., Courvoisier, D., Vuilleumier, N., Meyer, P., & Mach, F. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12480 · Cited by 46
Keep recycling going: new approaches to reduce LDL-C
Klein-Szanto, A. J. P., & Bassi, D. E. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.04.003 · Cited by 46
Deficiency of ASGR1 in pigs recapitulates reduced risk factor for cardiovascular disease in humans
Xie, B., Shi, X., Li, Y., Xia, B., Zhou, J., Du, M., Xing, X., Bai, L., Liu, E., Alvarez, F., et al. (2021) · PLOS Genetics · doi:10.1371/journal.pgen.1009891 · Cited by 46
Han, F., Liu, X., Chen, C., Liu, Y., Du, M., Guan, Y., Zhang, Y., Wang, D., Ahmed, M., Li, X., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0303-z · Cited by 46
Wang, D., Yang, X., Chen, Y., Gong, K., Yu, M., Gao, Y., Wu, X., Hu, H., Liao, C., Han, J., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015623 · Cited by 46
Inhibition of PCSK9: A Promising Enhancer for Anti-PD-1/PD-L1 Immunotherapy
Sun, S., Ma, J., Zuo, T., Shi, J., Sun, L., Meng, C., Shu, W., Yang, Z., Yao, H., & Zhang, Z. (2024) · Research · doi:10.34133/research.0488 · Cited by 46
In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial
Wan, P., Tang, S., Lin, D., Lu, Y., Long, M., Xiao, L., Jiang, Y., Liao, J., Ma, X., Liu, Y., et al. (2025) · Nature Medicine · doi:10.1016/j.atherosclerosis.2025.119507 · Cited by 47
Targeting modulated vascular smooth muscle cells in atherosclerosis via FAP-directed immunotherapy
Amrute, J., Jung, I., Yamawaki, T., Lin, W.-L., Bredemeyer, A. L., Diekmann, J., Hayat, S., Zhang, X., Wakefield, D. L., Luo, X., et al. (2026) · Science · doi:10.1126/science.adx1736 · Cited by 46
Kohli, P., Desai, N. R., Giugliano, R. P., Kim, J. B., Somaratne, R. M., Huang, F., Knüsel, B., McDonald, S. T., Abrahamsen, T. E., Wasserman, S. M., et al. (2012) · Clinical Cardiology · doi:10.1002/clc.22014 · Cited by 46
Fox, C. S., Hall, J. L., Arnett, D. K., Ashley, E. A., Delles, C., Engler, M. B., Freeman, M. W., Johnson, J. A., Lanfear, D. E., Liggett, S. B., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000211 · Cited by 46
Parhofer, K. G. (2012) · Core evidence · doi:10.2147/ce.s25239 · Cited by 46
Myśliwiec, M., Walczak, M., Małecka‐Tendera, E., Dobrzańska, A., Cybulska, B., Filipiak, K. J., Mazur, A., Jarosz-Chobot, P. A., Szadkowska, A., Rynkiewicz, A., et al. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.01.001 · Cited by 46
New treatment options for lipid-lowering therapy in subjects with type 2 diabetes
Scicali, R., Pino, A. D., Ferrara, V., Urbano, F., Piro, S., Rabuazzo, A. M., & Purrello, F. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-1089-4 · Cited by 46
Genetic Testing and Risk Scores: Impact on Familial Hypercholesterolemia
Sarraju, A., & Knowles, J. W. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00005 · Cited by 46
Endothelial Dysfunction in Dyslipidaemia: Molecular Mechanisms and Clinical Implications
Zarić, B. L., Obradovic, M. M., Trpković, A., Banach, M., Mikhailidis, D. P., & Isenović, E. R. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190903112146 · Cited by 46
Farnier, M. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283613a3d · Cited by 43
Self-citationChasing LDL cholesterol to the bottom — PCSK9 in perspective
Libby, P., & Tokgözoğlu, L. S. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00085-x · Cited by 46
Nishikido, T. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01752-4 · Cited by 46
Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells
Cao, A., Wu, M., Li, H., & Liu, J. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m010603 · Cited by 46
Mathematical Model for Low Density Lipoprotein (LDL) Endocytosis by Hepatocytes
Wattis, J. A. D., O’Malley, B., Blackburn, H., Pickersgill, L., Panovska‐Griffiths, J., Byrne, H. M., & Jackson, K. G. (2008) · Bulletin of Mathematical Biology · doi:10.1007/s11538-008-9347-9 · Cited by 46
The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy
Feng, Q., Wei, W.-Q., Chung, C. P., Levinson, R. T., Bastarache, L. A., Denny, J. C., & Stein, C. M. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.3 · Cited by 46
ToMMo Study Group, Yamaguchi‐Kabata, Y., Yasuda, J., Tanabe, O., Suzuki, Y., Kawame, H., Fuse, N., Nagasaki, M., Kawai, Y., Kojima, K., et al. (2017) · Journal of Human Genetics · doi:10.1038/s10038-017-0347-1 · Cited by 46
Clearance of plasma PCSK9 via the asialoglycoprotein receptor mediated by heterobifunctional ligands
Bagdanoff, J. T., Smith, T. M., Allan, M., O’Donnell, P. H., Nguyen, Z., Moore, E. A., Baird, J., Wang, S., Subramanian, V., Tigani, B., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2022.12.003 · Cited by 45
Lu, X., Zhang, M., Li, G., Zhang, S., Zhang, J., Fu, X., & Sun, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713202 · Cited by 45
PCSK9 inhibitors: current status and emerging frontiers in lipid control
Agnello, F. G., Mauro, M. S., Rochira, C., Landolina, D., Finocchiaro, S., Greco, A., Ammirabile, N., Raffo, C., Mazzone, P. M., Spagnolo, M., et al. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2288169 · Cited by 45
PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges
Norata, G. D., Tibolla, G., & Catapano, A. L. (2014) · Vascular Pharmacology · doi:10.1016/j.vph.2014.05.011 · Cited by 45
Fernández-Patrón, C., Kassiri, Z., & Leung, D. (2016) · Comprehensive physiology · doi:10.1002/cphy.c160010 · Cited by 45
Characterization of Proprotein Convertases and Their Involvement in Virus Propagation
Garten, W. (2018) · Springer eBooks · doi:10.1007/978-3-319-75474-1_9 · Cited by 45
Ahn, J., Kim, Y., Chae, H., Choi, Y. H., Ahn, H., Yoo, H., Kang, M., Kim, J., & Chin, Y. (2019) · Journal of Natural Products · doi:10.1021/acs.jnatprod.8b00748 · Cited by 45
Seidah, N. G., Pasquato, A., & Andréo, U. (2021) · Viruses · doi:10.3390/v13071229 · Cited by 40
Self-citationEarlier Intervention in the Management of Hypercholesterolemia
Steinberg, D. H. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.057 · Cited by 45
Drug discovery in the extracellular matrix
Huxley‐Jones, J., Foord, S. M., & Barnes, M. R. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.05.005 · Cited by 45
Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels
Abujrad, H., Mayne, J., Ruzicka, M., Cousins, M., Raymond, A., Cheesman, J. O., Taljaard, M., Sorisky, A., Burns, K. D., & Ooi, T. C. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.12.030 · Cited by 45
Lupattelli, G., VUONO, S. D., & Mannarino, E. (2011) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2011.04.010 · Cited by 45
Utility of genetic determinants of lipids and cardiovascular events in assessing risk
Holmes, M. V., Harrison, S., Talmud, P. J., Hingorani, A. D., & Humphries, S. E. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.6 · Cited by 44
Sinning, D., & Landmesser, U. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01427-6 · Cited by 44
Surf4, cargo trafficking, lipid metabolism, and therapeutic implications
Shen, Y., Gu, H.-M., Qin, S., & Zhang, D. (2022) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjac063 · Cited by 44
Early diagnosis and treatment of familial hypercholesterolemia: improving patient outcomes
Alonso, R., Mata, P., Zambón, D., Mata, N., & Fuentes, F. J. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.13.7 · Cited by 44
PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia
Verbeek, R., Stoekenbroek, R. M., & Hovingh, G. K. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.099 · Cited by 44
The evolving landscape of PCSK9 inhibition in cancer
Oza, P. P., & Kashfi, K. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175721 · Cited by 44
Campagna, F., Martino, F., Bifolco, M., Montali, A., Martino, E., Morrone, F., Antonini, R., Cantàfora, A., Verna, R., & Arca, M. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.11.015 · Cited by 44
Regional Distribution and Metabolic Effect of PCSK9 insLEU and R46L Gene Mutations and apoE Genotype
Awan, Z. A., DELVIN, E. E., Levy, E. H., Genest, J. J., Davignon, J., Seidah, N. G., & Baass, A. W. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.03.004 · Cited by 44
Self-citationProprotein convertases in high-density lipoprotein metabolism
Choi, S., & Korstanje, R. (2013) · Biomarker Research · doi:10.1186/2050-7771-1-27 · Cited by 44
Molecular basis of familial hypercholesterolemia
Bruikman, C. S., Hovingh, G. K., & Kastelein, J. J. P. (2017) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000385 · Cited by 35
Novel Therapeutic Targets for Managing Dyslipidemia
Sathiyakumar, V., Kapoor, K., Jones, S. R., Banach, M., Martin, S. S., & Toth, P. P. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.06.001 · Cited by 44
Whittall, R. A., Scartezini, M., Li, K., Hubbart, C., Reiner, Z., Abraha, A., Neil, H. A. W., Dedoussis, G., & Humphries, S. E. (2010) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/acb.2009.009076 · Cited by 43
Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
Wołowiec, Ł., Osiak, J., Wołowiec, A., Wijata, A., Grześk, E., Kozakiewicz, M., Banach, J., Nowaczyk, A., Nowaczyk, J., & Grześk, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020323 · Cited by 43
“The work published in 2003, which gave rise to research on the PCSK9 protein, was a discovery made in French families—in people without mutations in the LDLR or apolipoprotein B gene but with very high levels of LDL-C [39].”
BackgroundThe role of PCSK9 in inflammation, immunity, and autoimmune diseases
Frostegård, J. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2017281 · Cited by 43
“Also genetic variants which lead to high PCSK9 activity have been identified, which causes high LDL-levels and increased CVD risk [5].”
BackgroundNew developments in proprotein convertase subtilisin–kexin 9's biology and clinical implications
Seidah, N. G. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000295 · Cited by 43
Self-citationCaron, J., Pène, V., Tolosa, L., Villaret, M., Luce, E., Fourrier, A., Heslan, J.-M., Saheb, S., Bruckert, E., Gómez-Lechón, M. J., et al. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1342-6 · Cited by 43
PCSK9: from biology to clinical applications
Blanchard, V., Khantalin, I., Ramin-Mangata, S., Chémello, K., Nativel, B., & Lambert, G. (2019) · Pathology · doi:10.1016/j.pathol.2018.10.012 · Cited by 43
Fowler, A., Van Rompay, K. K. A., Sampson, M., Leo, J., Watanabe, J. K., Usachenko, J. L., Immareddy, R., Lovato, D. M., Schiller, J. T., Remaley, A. T., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00743-6 · Cited by 36
Further evidence of novel APOB mutations as a cause of familial hypercholesterolaemia
Alves, A. C., Benito‐Vicente, A., Medeiros, A. M., Reeves, K., Martín, C., & Bourbon, M. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.819 · Cited by 43
Gouni‐Berthold, I., Descamps, O. S., Fraass, U., Hartfield, E., Allcott, K., Dent, R. E., & März, W. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13066 · Cited by 43
Lavoie, J.-M. (2016) · World Journal of Hepatology · doi:10.4254/wjh.v8.i23.961 · Cited by 43
MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?
Momtazi‐Borojeni, A. A., Banach, M., Pirro, M., Stein, E. A., & Sahebkar, A. (2017) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8611-x · Cited by 43
Circulating low density lipoprotein (LDL)
Khosravi, M., Hosseini‐Fard, S. R., & Najafi, M. (2018) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2018-0024 · Cited by 43
Puteri, M. U., Azmi, N. U., Kato, M., & Saputri, F. C. (2022) · Life · doi:10.3390/life12020190 · Cited by 39
PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
Do, R. Q., Vogel, R. A., & Schwartz, G. G. (2013) · Current Cardiology Reports · doi:10.1007/s11886-012-0345-z · Cited by 43
Miyazawa, H., Honda, T., Miyauchi, S., Domon, H., Okui, T., Nakajima, T. E., Tabeta, K., & Yamazaki, K. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.09.023 · Cited by 43
Alghamdi, R. H., O'Reilly, P., Lu, C., Gomes, J., Lagace, T. A., & Basak, A. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.01.022 · Cited by 43
Benn, T., Kim, B., Park, Y., Yang, Y. J., Pham, T. X., Ku, C. S., Farruggia, C., Harness, E., Smyth, J. A., & Lee, J. (2015) · British Journal Of Nutrition · doi:10.1017/s0007114515001105 · Cited by 43
Gibbs, J. P., Doshi, S., Kuchimanchi, M., Grover, A., Emery, M. G., Dodds, M. G., Gibbs, M. A., Somaratne, R., Wasserman, S. M., & Blom, D. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.840 · Cited by 42
PCSK9 and the nervous system: a no-brainer?
Jaafar, A. K., Techer, R., Chemello, K., Lambert, G., & Bourane, S. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100426 · Cited by 42
“characterized by an elevation in circulating low-density lipoprotein cholesterol (LDL-C) and premature coronary heart disease (CHD) risk (2).”
BackgroundEmdin, C. A., Khera, A. V., Aragam, K., Haas, M., Chaffin, M., Klarin, D., Natarajan, P., Bick, A., Zekavat, S. M., Nomura, A., et al. (2019) · Diabetes · doi:10.2337/db18-0857 · Cited by 42
Tabeta, K., Hosojima, M., Nakajima, M., Miyauchi, S., Miyazawa, H., Takahashi, N., Matsuda, Y., Sugita, N., KOMATSU, Y., Sato, K., et al. (2018) · Journal of Periodontal Research · doi:10.1111/jre.12533 · Cited by 42
Ray, A., Alabarse, P. V. G., Malik, R., Sargurupremraj, M., Bernhagen, J., Dichgans, M., Baumeister, S., & Georgakis, M. K. (2025) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2025.06.001 · Cited by 42
New Therapies for Reducing Low-Density Lipoprotein Cholesterol
Stein, E. A., & Raal, F. J. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.08.008 · Cited by 42
Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression
Parker, R. A., Garcia, R., Ryan, C. S., Liu, X., Shipkova, P., Livanov, V., Patel, P., & Ho, S. P. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m038331 · Cited by 39
Cholesterol-Lowering Effect of Calcium Alginate in Rats
Idota, Y., Kogure, Y., Katō, T., Ogawa, M., Kobayashi, S., Kakinuma, C., Yano, K., Arakawa, H., Miyajima, C., Kasahara, F., et al. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00503 · Cited by 42
Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012
Hwang, T. J., Lauffenburger, J. C., Franklin, J. M., & Kesselheim, A. S. (2016) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2016.03.012 · Cited by 42
The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies
Lambert, G. C., Thedrez, A., Croyal, M., Ramin‐Mangata, S., Couret, D., Diotel, N., Nobécourt, E., Krempf, M., LeBail, J. C., Poirier, B., et al. (2017) · Clinical Science · doi:10.1042/cs20160403 · Cited by 42
Self-citation
Metadata
- Authors
- Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derré, A., Villéger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J.-M., Luc, G., Moulin, P., Weissenbach, J., Prat, A., Krempf, M., Junien, C., Seidah, N. G., & Boileau, C.
- Affiliations
- Hôpital Necker-Enfants Malades (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Genoscope (FR)
- Montreal Clinical Research Institute (CA)
- Pitié-Salpêtrière Hospital (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Hôpital Claude Huriez (FR)
- Hospices Civils de Lyon (FR)
- ORCID
- Venue
- Nature Genetics
- Published
- 2003-05-05
- Volume
- 34
- Issue
- 2
- Pages
- 154-156
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2040612932
- Semantic Scholar
- 80bf33c74bfe780bcc1968f318b09647e59f0afe
- Cited by
- 2,985
- References
- 6
- Citations by year
- 2026: 88 · 2025: 115 · 2024: 154 · 2023: 175 · 2022: 163 · 2021: 207 · 2020: 182 · 2019: 173 · 2018: 214 · 2017: 232 · 2016: 214 · 2015: 200 · 2014: 162 · 2013: 131 · 2012: 101
- FWCI
- 38.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Institut National de la Santé et de la Recherche Médicale
- Fondation de France
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- PCSK9, autosomal dominant hypercholesterolemia, LDL receptor, apolipoprotein B, LDL cholesterol, genetic mutations, cholesterol homeostasis, subtilases, coronary heart disease risk
- MeSH terms
- Proprotein Convertase 9, Chromosomes, Human, Pair 1, Female, Genes, Dominant, Humans, Hyperlipoproteinemia Type II, Genetic Linkage, Liver, Male, Mutation, Pedigree, Serine Endopeptidases, Amino Acid Substitution, Proprotein Convertases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.